RALEIGH, N.C., Jan. 4, 2021 /PRNewswire/ -- Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that results from its multi-dose study of BRYN-NDS1C (bi-dose epinephrine nasal spray), have been accepted for presentation at the 2021 American Academy of Asthma, Allergy and Immunology (AAAAI) annual meeting to be held virtually February 26 to March 1, 2021.
The study presentation will highlight the favorable release profile, pharmacokinetic and pharmacodynamic outcomes of epinephrine when administered with one spray from Bryn's two-dose nasal spray device as compared to those seen with administration by a single 0.3 mg epinephrine auto-injector. Presentations will be available to attendees via the conference website.
"We are very encouraged by the findings from our multi-dose study comparing the bioavailability and cardiovascular effects of a single spray from our bi-dose nasal device with a single 0.3 mg auto-injector and look forward to sharing the results with the allergy community," said David Dworaczyk, Ph.D., CEO of Bryn Pharma. "Our goal at Bryn Pharma is to provide patients at risk for anaphylaxis the advantages inherent in our small nasal spray, including its easy use and carry design, needle-free delivery, and the convenience of two doses of drug within a single device. We look forward to completing the remaining steps required to gain FDA approval."
READ ARTICLE